NDAQ:ICPT - Post Discussion
Post by
AviseAnalytics on Feb 11, 2022 7:34am
CAN INTERCEPT MAKE IT TO THE FINISHING LINE IN NASH?
$ICPT
Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) is a biopharmaceutical Company aiming to create novel therapeutics for the treatment of progressive non-viral liver diseases. The Company has upcoming catalysts in the form of the topline data from a crucial Phase 3 REVERSE trial , a active late-stage Phase 3 study that is evaluating compensated cirrhosis due to NASH.
Read on to find out more!
Be the first to comment on this post